KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is expected to post earnings of -$0.91 per share

0

Analysts expect KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) to report earnings of ($0.91) per share for the current fiscal quarter, according to Zacks. Zero analysts provided earnings estimates for KalVista Pharmaceuticals, with estimates ranging from ($1.05) to ($0.79). KalVista Pharmaceuticals posted earnings per share of ($0.56) in the same quarter last year, indicating a negative year-over-year growth rate of 62.5%. The company is expected to announce its next earnings report on Thursday, March 10.

On average, analysts expect KalVista Pharmaceuticals to report full year earnings of ($3.37) per share for the current year, with EPS estimates ranging from ($3.82) to ($3. $.05). For the next fiscal year, analysts expect the company to report earnings of ($3.54) per share, with EPS estimates ranging from ($4.29) to ($2.69). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research companies that cover KalVista Pharmaceuticals.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its results on Thursday, December 9. The specialty pharma company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.01).

KALV has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. SVB Leerink reiterated a “buy” rating and set a price target of $51.00 on shares of KalVista Pharmaceuticals in a Sunday, December 12 research report. Finally, Needham & Company LLC lowered its price target on KalVista Pharmaceuticals shares from $50.00 to $48.00 and set a “buy” rating for the company in a Friday, Dec. 10 research note. . One analyst rated the stock with a hold rating and four rated the stock with a buy rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $46.60.

(A d)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Several institutional investors and hedge funds have recently changed their holdings in the company. Geode Capital Management LLC increased its stake in shares of KalVista Pharmaceuticals by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 377,970 shares of the specialty pharmaceutical company valued at $5,000,000 after purchasing an additional 9,830 shares during the period. Charles Schwab Investment Management Inc. increased its stake in KalVista Pharmaceuticals by 10.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 57,415 shares of the specialty pharmaceutical company worth $760,000 after acquiring an additional 5,317 shares during the period. JPMorgan Chase & Co. increased its stake in KalVista Pharmaceuticals by 18.2% in the fourth quarter. JPMorgan Chase & Co. now owns 10,747 shares of the specialty pharmaceutical company worth $142,000 after acquiring 1,656 additional shares during the period. Rafferty Asset Management LLC increased its stake in KalVista Pharmaceuticals by 66.3% in the fourth quarter. Rafferty Asset Management LLC now owns 64,186 shares of the specialty pharmaceutical company worth $849,000 after acquiring an additional 25,586 shares during the period. Finally, Citigroup Inc. increased its stake in KalVista Pharmaceuticals by 86.7% in the fourth quarter. Citigroup Inc. now owns 54,127 shares of the specialty pharmaceutical company worth $716,000 after acquiring an additional 25,139 shares during the period.

KalVista Pharmaceuticals Shares opened at $15.06 on Friday. KalVista Pharmaceuticals has a 1-year low of $10.79 and a 1-year high of $43.08. The stock has a market capitalization of $368.52 million, a price-earnings ratio of -5.64 and a beta of 1.93. The company has a fifty-day moving average price of $13.11 and a 200-day moving average price of $16.62.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops and markets small molecule protease inhibitors for diseases with unmet needs. The Company’s product portfolio includes small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured articles

Get a Free Copy of Zacks’ Research Report on KalVista Pharmaceuticals (KALV)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for KalVista Pharmaceuticals (NASDAQ: KALV)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in KalVista Pharmaceuticals right now?

Before you consider KalVista Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and KalVista Pharmaceuticals wasn’t on the list.

Although KalVista Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Share.

Comments are closed.